Italia markets close in 3 hours 17 minutes
FTSE MIB
34.252,06 +312,31 (+0,92%) Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,24 +0,67 (+0,80%) Bitcoin EUR
60.036,43 +322,13 (+0,54%)
Neurocrine Biosciences, Inc. (NBIX)
NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 04:00PM EDT
Preborsa:
| Chiusura precedente | 138,97 |
| Aperto | 139,37 |
| Denaro | 137,68 x 100 |
| Lettera | 137,81 x 100 |
| Min-Max giorno | 136,06 - 139,37 |
| Intervallo di 52 settimane | 89,04 - 148,37 |
| Volume | |
| Media Volume | 885.879 |
| Capitalizzazione | 13,856B |
| Beta (5 anni mensile) | 0,28 |
| Rapporto PE (ttm) | 55,77 |
| EPS (ttm) | 2,47 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | 29 dic 1995 |
| Stima target 1A | 153,29 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.